search
Back to results

The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery

Primary Purpose

Pain, Postoperative, Opioid Use

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Intravenous Lidocaine Infusion
Placebo Infusion
Sponsored by
University of Vermont Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring lidocaine, lumbar spine surgery, postoperative pain, opioid reduction

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient undergoing one- or two-level posterior lumbar fusion with or without decompression at University of Vermont Medical Center
  • 18-75 years of age
  • Signed consent form

Exclusion Criteria:

  • Allergy to lidocaine
  • Contraindication to lidocaine, such as substantial hepatic impairment (alanine aminotransferase or aspartate transaminase more than twice normal), renal impairment (serum creatinine >2 mg/dl)
  • Seizures or a history of seizure disorder
  • Congestive heart failure
  • Arrythmias
  • Chronic opioid use >45 mg morphine equivalent per day
  • Trauma patients
  • Inter-body fusions
  • Severe psychiatric comorbidities
  • Planned epidural anesthesia or analgesia

Sites / Locations

  • University of Vermont Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intravenous Lidocaine Infusion

Placebo Infusion

Arm Description

Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.

Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.

Outcomes

Primary Outcome Measures

Total morphine equivalent consumed at 24 hours after surgery
Subjects will receive a patient-controlled analgesia pump for the first 24 hours after surgery. Total morphine equivalent will be calculated according to the Centers for Disease Control and Prevention conversion factor for calculating morphine milligram equivalents.

Secondary Outcome Measures

Total morphine equivalent consumed at 48 hours after surgery
Electronic medical records will be reviewed to total opioids received after the patient-controlled analgesia pump is discontinued. Total morphine equivalent will be calculated according to the Centers for Disease Control and Prevention conversion factor for calculating morphine milligram equivalents.
Pain score 4 hours post-operation
Visual analog scale pain scores 4 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Pain score 10 hours post-operation
Visual analog scale pain scores 10 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Pain score 24 hours post-operation
Visual analog scale pain scores 24 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Pain score 48 hours post-operation
Visual analog scale pain scores 48 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Quality of Recovery Score 36 hours post-operation
Subjects will complete the 15-question Quality of Recovery 36 hours after the end of surgery. Scores will be compared to the baseline taken in the pre-operative hold area.
Quality of Recovery Score 48 hours post-operation
Subjects will complete the 15-question Quality of Recovery 48 hours after the end of surgery. Scores will be compared to the baseline taken in the pre-operative hold area.
Length of Stay
Length of stay in the hospital, defined as time between admission and discharge. Unit of measure: Days.
Incidence of nausea
A count of the incidences of treatment of nausea with medication.
Time to first flatus
Time of first flatus will be recorded by floor nurses and extracted from the electronic medical record. Unit of measure: Hours.
Time to first bowel movement
Time of first bowel movement will be recorded by floor nurses and extracted from the electronic medical record. Unit of measure: Hours.

Full Information

First Posted
June 13, 2018
Last Updated
January 27, 2023
Sponsor
University of Vermont Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03624985
Brief Title
The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery
Official Title
The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Terminated
Why Stopped
Subjects had a high dropout rate. Of 61 consented, 24 did not participate. Reasons: Surgical cancellations; changing procedure type after consent; and staffing issues. The dropout rate of 39% was considered a barrier to publication.
Study Start Date
June 4, 2018 (Actual)
Primary Completion Date
October 14, 2019 (Actual)
Study Completion Date
October 14, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vermont Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether an infusion of lidocaine during surgery can reduce the need for postoperative opioid pain medication use in patients undergoing lumbar spine surgery. Participants will be recruited by spine surgeons from their pool of patients who are presenting for surgery at University of Vermont Medical Center. If they agree to participate, patients will be assigned at random to receive either an infusion of lidocaine during surgery, or an infusion of saline with 5% dextrose. Subjects will also be asked to complete a 15-item questionnaire that asks about health, quality of life, and level of pain, at three timepoints. Patients will also be asked to rate their level of pain at multiple timepoints after surgery, and we will collect the additionally data from patients' medical records.
Detailed Description
Lidocaine has analgesic and anti-inflammatory effects. It has been shown to reduce early postoperative pain and nausea. Additionally, lidocaine has been shown to have positive effects in the recovery of bowel function, with a reduction in time to first flatus, first bowel sounds, first bowel movement, and is associated with a reduction of ileus. Because of these facts, lidocaine infusion has become part of enhanced recovery pathways after bowel surgery at our institution and others. There are few trials examining the use of lidocaine for orthopedic procedures and many of these studies have contradictory adults. An article by Martin et al. found no benefit in pain or recovery after total hip arthroplasty. By contrast, Farag and colleagues found that lidocaine significantly improves postoperative pain after major spine surgery. Additionally, quality of life scores at one and three months after surgery were significantly higher in the lidocaine group. When our Spine Surgery Analgesic Protocol for major spine surgery at University of Vermont Medical Center was revised in 2015, a lidocaine infusion was added to the protocol. Studies for lidocaine use in minor lumbar surgery are scant. In one study of 50 patients in Korea, patient pain scores and fentanyl consumption were significantly lower in the lidocaine infusion group (1.5 mg/kg bolus plus 2 mg/kg/hr infusion) at 2, 4, 8, 12 and 24 hours after surgery. Of note, the Cleveland Clinic Outcomes group is currently enrolling 440 patients in a study in which half will receive lidocaine and ketamine infusions. A reduction in opioid use may lead to the potential reduction of opioid-related side effects, such as nausea, constipation, and hyperalgesia, as well as more serious consequences such as respiratory depression and abuse. There is also the possibility of a length of stay reduction which has potential financial benefits. This is a randomized, controlled, double-blind study involving patients undergoing one- or two-level posterior lumbar instrumented spinal fusion with or without decompression. The University of Vermont Medical Center operating rooms will be utilized for this investigation. For the study group, we plan to prospectively recruit 140 patients 18-75 years of age. Recruitment will be done by the participating orthopedists and neurosurgeons, from their own patients. After an informed consent discussion, patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min (intervention arm) or no lidocaine (control arm). All patients will receive adequate pain control medication according to their needs. Subjects will complete the 15-question Quality of Recovery assessment at baseline and at 36 and 60 hours after surgery. Using the electronic medical system, the following information with extracted: Total morphine equivalent used in house at 36 hours, total morphine equivalents used at 60 hours, visual analog scale pain scores at 4, 8, 12, 24, 36, and 60 hours, length of stay, incidence of nausea requiring medication, time to first flatus, and time to first bowel movement. Subjects will receive a patient-controlled analgesia pump for the first 36 hours after surgery. Randomization will be performed by the University of Vermont Medical Center Investigational Pharmacy Drug Service (IDS). IDS will generate a table of random numbers and assign those numbers in a 1:1 ratio of active drug to placebo, in blocks of 4. Following informed consent, a member of the study team will notify IDS, which will prepare syringes for the bolus dose and a bag for the infusion, both containing either active drug or placebo. The syringes and bag will be labeled with the subject's name, medical record number, and randomization number.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Opioid Use
Keywords
lidocaine, lumbar spine surgery, postoperative pain, opioid reduction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Randomized, controlled, double-blind study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intravenous Lidocaine Infusion
Arm Type
Experimental
Arm Description
Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
Arm Title
Placebo Infusion
Arm Type
Placebo Comparator
Arm Description
Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
Intervention Type
Drug
Intervention Name(s)
Intravenous Lidocaine Infusion
Other Intervention Name(s)
IV Lidocaine Infusion
Intervention Description
Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
Intervention Type
Drug
Intervention Name(s)
Placebo Infusion
Other Intervention Name(s)
Placebo, Control, Comparator
Intervention Description
Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
Primary Outcome Measure Information:
Title
Total morphine equivalent consumed at 24 hours after surgery
Description
Subjects will receive a patient-controlled analgesia pump for the first 24 hours after surgery. Total morphine equivalent will be calculated according to the Centers for Disease Control and Prevention conversion factor for calculating morphine milligram equivalents.
Time Frame
24 hours postoperatively
Secondary Outcome Measure Information:
Title
Total morphine equivalent consumed at 48 hours after surgery
Description
Electronic medical records will be reviewed to total opioids received after the patient-controlled analgesia pump is discontinued. Total morphine equivalent will be calculated according to the Centers for Disease Control and Prevention conversion factor for calculating morphine milligram equivalents.
Time Frame
48 hours postoperatively
Title
Pain score 4 hours post-operation
Description
Visual analog scale pain scores 4 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Time Frame
4 hours postoperatively
Title
Pain score 10 hours post-operation
Description
Visual analog scale pain scores 10 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Time Frame
10 hours postoperatively
Title
Pain score 24 hours post-operation
Description
Visual analog scale pain scores 24 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Time Frame
24 hours postoperatively
Title
Pain score 48 hours post-operation
Description
Visual analog scale pain scores 48 hours after the end of the operation. The visual analog scale is presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." The patient marks a point on the line that matches the amount of pain they feel. 0 = no pain 100 = worst pain imaginable
Time Frame
48 hours postoperatively
Title
Quality of Recovery Score 36 hours post-operation
Description
Subjects will complete the 15-question Quality of Recovery 36 hours after the end of surgery. Scores will be compared to the baseline taken in the pre-operative hold area.
Time Frame
36 hours postoperatively
Title
Quality of Recovery Score 48 hours post-operation
Description
Subjects will complete the 15-question Quality of Recovery 48 hours after the end of surgery. Scores will be compared to the baseline taken in the pre-operative hold area.
Time Frame
48 hours postoperatively
Title
Length of Stay
Description
Length of stay in the hospital, defined as time between admission and discharge. Unit of measure: Days.
Time Frame
During hospitalization, approximately 5 days
Title
Incidence of nausea
Description
A count of the incidences of treatment of nausea with medication.
Time Frame
During hospitalization, approximately 5 days
Title
Time to first flatus
Description
Time of first flatus will be recorded by floor nurses and extracted from the electronic medical record. Unit of measure: Hours.
Time Frame
96 hours postoperatively
Title
Time to first bowel movement
Description
Time of first bowel movement will be recorded by floor nurses and extracted from the electronic medical record. Unit of measure: Hours.
Time Frame
96 hours postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient undergoing one- or two-level posterior lumbar fusion with or without decompression at University of Vermont Medical Center 18-75 years of age Signed consent form Exclusion Criteria: Allergy to lidocaine Contraindication to lidocaine, such as substantial hepatic impairment (alanine aminotransferase or aspartate transaminase more than twice normal), renal impairment (serum creatinine >2 mg/dl) Seizures or a history of seizure disorder Congestive heart failure Arrythmias Chronic opioid use >45 mg morphine equivalent per day Trauma patients Inter-body fusions Severe psychiatric comorbidities Planned epidural anesthesia or analgesia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy Dominick, MD
Organizational Affiliation
Anesthesiologist
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Lunardini, MD
Organizational Affiliation
Orthopedic Surgeon
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Vermont Medical Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
10969322
Citation
Hollmann MW, Durieux ME. Local anesthetics and the inflammatory response: a new therapeutic indication? Anesthesiology. 2000 Sep;93(3):858-75. doi: 10.1097/00000542-200009000-00038. No abstract available.
Results Reference
background
PubMed Identifier
18844267
Citation
Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. Br J Surg. 2008 Nov;95(11):1331-8. doi: 10.1002/bjs.6375.
Results Reference
background
PubMed Identifier
18580181
Citation
Martin F, Cherif K, Gentili ME, Enel D, Abe E, Alvarez JC, Mazoit JX, Chauvin M, Bouhassira D, Fletcher D. Lack of impact of intravenous lidocaine on analgesia, functional recovery, and nociceptive pain threshold after total hip arthroplasty. Anesthesiology. 2008 Jul;109(1):118-23. doi: 10.1097/ALN.0b013e31817b5a9b.
Results Reference
background
PubMed Identifier
23681143
Citation
Farag E, Ghobrial M, Sessler DI, Dalton JE, Liu J, Lee JH, Zaky S, Benzel E, Bingaman W, Kurz A. Effect of perioperative intravenous lidocaine administration on pain, opioid consumption, and quality of life after complex spine surgery. Anesthesiology. 2013 Oct;119(4):932-40. doi: 10.1097/ALN.0b013e318297d4a5.
Results Reference
background
PubMed Identifier
24216403
Citation
Kim KT, Cho DC, Sung JK, Kim YB, Kang H, Song KS, Choi GJ. Intraoperative systemic infusion of lidocaine reduces postoperative pain after lumbar surgery: a double-blinded, randomized, placebo-controlled clinical trial. Spine J. 2014 Aug 1;14(8):1559-66. doi: 10.1016/j.spinee.2013.09.031. Epub 2013 Nov 8.
Results Reference
background

Learn more about this trial

The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery

We'll reach out to this number within 24 hrs